Alirocumab for the treatment of hyperlipidemia in high-risk patients: an updated review.

about

Alirocumab for the treatment of hyperlipidemia in high-risk patients: an updated review.

Item

http://www.wikidata.org/entity/Q47419614

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Alirocumab for the treatment of hyperlipidemia in high-risk patients: an updated review.

@en

Alirocumab for the treatment of hyperlipidemia in high-risk patients: an updated review.

@nl

type

Item

label

Alirocumab for the treatment of hyperlipidemia in high-risk patients: an updated review.

@en

Alirocumab for the treatment of hyperlipidemia in high-risk patients: an updated review.

@nl

prefLabel

Alirocumab for the treatment of hyperlipidemia in high-risk patients: an updated review.

@en

Alirocumab for the treatment of hyperlipidemia in high-risk patients: an updated review.

@nl

P1476

Alirocumab for the treatment of hyperlipidemia in high-risk patients: an updated review.

@en

P2093

Michel Farnier

http://www.w3.org/2001/XMLSchema#string

P2860

Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences

PCSK9: a key modulator of cardiovascular health

Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management

Mutations in PCSK9 cause autosomal dominant hypercholesterolemia

Sequence variations in PCSK9, low LDL, and protection against coronary heart disease

2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

Safety of Very Low Low-Density Lipoprotein Cholesterol Levels With Alirocumab: Pooled Data From Randomized Trials.

Effect of alirocumab dose increase on LDL lowering and lipid goal attainment in patients with dyslipidemia.

Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk.

Efficacy and safety of alirocumab in patients with hypercholesterolemia not adequately controlled with non-statin lipid-lowering therapy or the lowest strength of statin: ODYSSEY NIPPON study design and rationale.

P304

923-932

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/14779072.2017.1409115

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-11-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29171769

http://www.w3.org/2001/XMLSchema#string

P921

hyperlipidemia